Ali Habib, MD
Neuromuscular Medicine · Orange, CANPI 1518124288
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.6%. 2025 is the largest year on record at $171,433, more than ten times the $13,951 reported in 2019. Among neuromuscular medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 405 payments — averaging $1099.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$100K
- UCB, Inc.$84K
- UCB SA$80K
- Argenx US, Inc.$78K
- Amgen$36K
- Johnson & Johnson$22K
- plus $44K from 23 others
Across 205 payments — averaging $5807.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$211K
- AstraZeneca$172K
- Regeneron$171K
- Argenx US, Inc.$151K
- Amgen$118K
- Novartis$112K
- plus $254K from 8 others
What the payments were for
- Consulting fees$230,47852%
- Speaking & faculty fees$151,89234%
- Travel & lodging$51,39912%
- Food & beverage$11,3473%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 111 | $100,410 |
| UCB, Inc. | 66 | $84,474 |
| UCB SA | 19 | $80,031 |
| Argenx US, Inc. | 89 | $78,039 |
| Amgen | 24 | $36,188 |
| Johnson & Johnson(2 entities) | 18 | $22,203 |
| F. Hoffmann-la Roche AG | 6 | $11,596 |
| Genentech, Inc. | 10 | $6,139 |
| Grifols USA, LLC | 20 | $5,004 |
| Janssen Scientific Affairs, LLC | 3 | $3,638 |
| Novartis | 2 | $3,430 |
| Grifols Shared Services North America, Inc. | 6 | $2,524 |
| Pfizer | 1 | $2,500 |
| Merck Kgaa | 2 | $2,193 |
| GC Biopharma USA, Inc. | 1 | $2,000 |
| Amylyx Pharmaceuticals, Inc. | 1 | $1,500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,360 |
| Regeneron | 4 | $832 |
| CSL Behring | 5 | $249 |
| Roche Products Limited | 2 | $245 |
| Sarepta Therapeutics, Inc. | 3 | $153 |
| Catalyst Pharmaceuticals, Inc. | 1 | $131 |
| Biogen | 1 | $121 |
| Octapharma USA, Inc. | 2 | $84 |
| Sanofi | 2 | $50 |
| Tanabe Pharma America, Inc. | 1 | $33 |
| EMD Serono Research & Development Institute, Inc. | 1 | $27 |
| EDW Pharma, Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 2 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$445,173 in reported general payments places this provider in the 95th percentile of 44 neuromuscular medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc | 22 | $1,342,893 |
| SolirisEculizumab | 13 | $522,434 |
| VyvgartEfgartigimod Alfa-Fcab | 21 | $519,342 |
| RystiggoRozanolixizumab-Noli | 14 | $478,350 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 46 | $470,728 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 29 | $276,890 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 22 | $231,789 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 16 | $137,980 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 11 | $71,801 |
| XembifyImmune Globulin,gamma(Igg)klhw | 26 | $68,718 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 12 | $52,228 |
| MethotrexateMethotrexate Sodium | 56 | $2,582 |
| Prednisone | 97 | $998 |
| Pyridostigmine Bromide | 30 | $906 |
| Azathioprine | 14 | $770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Argenx US, Inc.Vyvgart Hytrulo, Vyvgart | $78,039 | $1,862,23543 claims |
| AstraZenecaSoliris | $100,410 | $522,43413 claims |
| UCB, Inc.Rystiggo | $84,474 | $478,35014 claims |
| CSL BehringPrivigen | $249 | $470,72846 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $1,360 | $276,89029 claims |
| Grifols USA, LLCGamunex-C, Xembify | $5,004 | $206,69842 claims |
| PfizerOctagam | $2,500 | $71,80111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 44 neuromuscular medicine providers in California.
Other neuromuscular medicine in Orange
- Tahseen MozaffarOrange$428K
- Namita GoyalOrange$174K
- Jay HanOrange$126K
- Khalid AlrasheedOrange$75K
- Jeffrey MullenOrange$13K
- Jonathan CauchiOrange$895
- Mona Rezaei MirghaedOrange$673
- Samir MacwanRancho Mirage$983K
- Jeffrey RosenfeldFresno$361K
- John DayStanford$294K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.